|
16.12.2024 14:51:54
|
Edgewise Therapeutics Announces Positive Topline Results From CANYON Phase 2 Trial Of Sevasemten
(RTTNews) - Edgewise Therapeutics, Inc.(EWTX), a muscle disease biopharmaceutical company, announced Monday positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy.
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies.
The trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date and the first to achieve its primary endpoint.
As for the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assessment (NSAA) with a trend towards improvement at 12 months compared to placebo .
Sevasemten was also well-tolerated and no new safety concerns were observed.
Nachrichten zu Edgewise Therapeutics Inc Registered Shs
| Keine Nachrichten verfügbar. |
Analysen zu Edgewise Therapeutics Inc Registered Shs
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Edgewise Therapeutics Inc Registered Shs | 26.99 | -0.72% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht fester aus dem Handel -- US-Handel endet mit Aufschlägen -- DAX schliesst nach neuem Rekord freundlich -- Börsen in Fernost letztlich mehrheitlich im PlusDer heimische Aktienmarkt zeigte sich am Donnerstag im Plus. Der deutsche Aktienmarkt notierte höher. Die US-Börsen schlossen höher. Asiens Börsen verbuchten am Donnerstag überwiegend Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |